It is note worthy here that the genetic basis (e.g., Myc or other oncogenes) for why the PDAC and CRC tumor lines tested in this study are vulnerable to CMG suppression is not known.[8] Nonetheless, such studies and the potential for Myc to create a tumor-selective reserve MCM vulnerability in many human neoplasms strongly suggest that CMGi intervention may offer an innovative means of managing cancer in the clinic. Here, MYC is linked to neoplasm.